These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 9220058

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR.
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [Abstract] [Full Text] [Related]

  • 3. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
    Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ.
    J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1140-6. PubMed ID: 7559307
    [Abstract] [Full Text] [Related]

  • 4. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C, Boidein F.
    Encephale; 2001 Sep; 27(5):435-43. PubMed ID: 11760693
    [Abstract] [Full Text] [Related]

  • 5. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL, Sahl R, Hardan AY.
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V, Kim YS, Scahill L.
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Popper CW.
    Child Adolesc Psychiatr Clin N Am; 2000 Jul; 9(3):605-46, viii. PubMed ID: 10944659
    [Abstract] [Full Text] [Related]

  • 15. Clonidine for treatment of attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1996 Dec 06; 38(989):109-10. PubMed ID: 8957471
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC, Fiske K, Lyne A.
    Clin Ther; 2007 Sep 06; 29(9):1967-79. PubMed ID: 18035196
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.